{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Participants must be informed that their participation is voluntary. Participants', 'or their legally authorized representative will be required to sign a statement of', 'informed consent that meets the requirements of 21 CFR 50, local regulations,', 'ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA)', 'requirements, where applicable, and the IRB/IEC or study center.', 'The medical record must include a statement that written informed consent was', 'obtained before the participant was enrolled in the study and the date the written', 'consent was obtained. The authorized person obtaining the informed consent', 'must also sign the ICF.', 'Participants must be re-consented to the most current version of the ICF(s)', 'during their participation in the study.', \"A copy of the ICF(s) must be provided to the participant or the participant's\", 'legally authorized representative.', 'Data Protection', 'Participants will be assigned a unique identifier by the sponsor. Any participant', 'records or datasets that are transferred to the sponsor will contain the identifier', 'only; participant names or any information which would make the participant', 'identifiable will not be transferred.', 'The participant must be informed that his/her personal study-related data will be', 'used by the sponsor in accordance with local data protection law. The level of', 'disclosure must also be explained to the participant.', 'The participant must be informed that his/her medical records may be examined', 'by Clinical Quality Assurance auditors or other authorized personnel appointed', 'by the sponsor, by appropriate IRB/IEC members, and by inspectors from', 'regulatory authorities.', 'Committees Structure', 'An IRC will be utilized to assess response and progression and primary endpoint of', 'the study. GSK will require the site to send electronic files (typically in DICOM', 'format) with acquired imaging for independent review. Details on scan acquisition', 'and image transferal are provided in the Scanning Reference Manual. Further details', 'on the IRC process will be defined in the IRC charter Results from the IRC will not', 'be provided to the investigative sites during the study.', 'Participant data to be shared with the IRC may include the following:', 'Scans (CT, MRI, or PET CT- whichever applicable)', 'SPEP, UPEP, M-protein in 24 hr. urine collection immunoelectrophoresis-', 'urine and serum, serum calcium, and albumin (unless reported as albumin', 'corrected),', 'Serum kappa, serum lambda FLC, FLC Ratio', 'MRD results', '112']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Publication Policy', 'The results of this study may be published or presented at scientific meetings. If', 'this is foreseen, the investigator agrees to submit all manuscripts or abstracts to', 'the sponsor before submission. This allows the sponsor to protect proprietary', 'information and to provide comments.', 'The sponsor will comply with the requirements for publication of study results.', 'In accordance with standard editorial and ethical practice, the sponsor will', 'generally support publication of multicenter studies only in their entirety and not', 'as individual site data. In this case, a coordinating investigator will be', 'designated by mutual agreement.', 'Authorship will be determined by mutual agreement and in line with', 'International Committee of Medical Journal Editors authorship requirements.', 'Dissemination of Clinical Study Data', 'For studies conducted in the EU under Regulations EU 536/2014: Consider whether', 'submission of results of the clinical study will be delayed more than one year after the', 'end of trial and provide substantiated reasons. Provide justification if a single summary of', 'results report will not be submitted for all study treatments used in the clinical study.', 'Disclosure of CSRs, periodic safety reports, and clinical study summary reports', 'after review by regulatory authorities. This includes access to CSRs from studies', 'with negative outcomes and from terminated development programs.', 'The posting of company-sponsored study information and tabular study results', \"on the US National Institutes of Health's website www.ClinTrials.gov and other\", 'publicly-accessible sites.', 'Publication planning and other activities related to non-promotional, peer-', 'reviewed publications, to ensure the scientific integrity and credibility of', 'publication activities performed by or on behalf of the company. The granting of', 'access to analyzable datasets from clinical studies through a secure system,', 'following an independent assessment of the scientific merit of a rigorously', 'defined research question from a third party.', 'Where required by applicable regulatory requirements, an investigator signatory', 'will be identified for the approval of the clinical study report. The investigator', 'will be provided reasonable access to statistical tables, figures, and relevant', 'reports and will have the opportunity to review the complete study results at a', 'GSK site or other mutually-agreeable location.', 'GSK will also provide the investigator with the full summary of the study', 'results. The investigator is encouraged to share the summary results with the', 'study participants, as appropriate.', 'The procedures and timing for public disclosure of the results summary and for', 'development of a manuscript for publication will be in accordance with GSK', 'Policy.', '113']\n\n###\n\n", "completion": "END"}